Sk Life Science, Inc.

This study tests whether cenobamate, an experimental anti-epileptic drug, can safely reduce primary generalized tonic-clonic (PGTC) seizures when added to a person's usual seizure medications. Adults and adolescents aged 12 and older with PGTC seizures are randomly assigned to re…

This study looked at the long-term safety of the drug cenobamate when added to existing treatment for people with primary generalized tonic-clonic seizures. A total of 147 participants who completed an earlier study took cenobamate for up to 52 weeks. Researchers tracked side eff…

This study tested a drug called cenobamate in 519 adults with partial onset seizures (focal seizures). Participants took cenobamate or a placebo alongside their usual seizure medications. The goal was to see if cenobamate could safely reduce seizure frequency. Results showed a si…

This study tested a medicine called cenobamate in 26 children with partial-onset seizures. The goal was to see how the drug moves through the body and if it is safe. The study did not aim to cure or control seizures long-term, but to gather important information for future use.